WebDisclosure WebDisclosure
Basculer en Français
8708 Companies
151765 Keywords
87442 Articles
81540 Press releases
Headlines Articles Press releases Scale Shift Ventures Remove
  1. Home
  2. Companies
  3. Scale Shift Ventures
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 07/16/2024 at 21:05, 10 months 24 days ago

    Leading Real Estate Technology Company Repliers Secures Seed Funding From Scale Shift Ventures

    Innovation Real Estate AI Technology PropTech Seed Funding
  • BRIEF

    published on 07/16/2024 at 21:05, 10 months 24 days ago

    Repliers, une entreprise leader dans le domaine des technologies immobilières, obtient un financement de démarrage auprès d'entreprises de changement d'échelle

    Innovation Immobilier Technologie IA PropTech Financement De Démarrage
  • PRESS RELEASE

    published on 07/16/2024 at 21:00, 10 months 24 days ago

    Leading Real Estate Technology Company Repliers Secures Seed Funding From Scale Shift Ventures

    Canadian proptech company Repliers secures seed funding from Scale Shift Ventures to democratize access to cutting-edge real estate technology. Investment supports expansion and rebranding effort
    Real Estate Technology PropTech Seed Funding Repliers Scale Shift Ventures
Accesswire
  • Published on 06/09/2025 at 22:30, 4 hours 25 minutes ago

    CANEX Announces Intention to Make a Takeover Bid to Acquire All of the Outstanding Shares of Gold Basin Resources

  • Published on 06/09/2025 at 22:15, 4 hours 40 minutes ago

    REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series

  • Published on 06/09/2025 at 19:52, 7 hours 3 minutes ago

    Taranis Issued Exploration Permit That Will Allow Efficient Drilling of Intrusive Target from Main Access Road at Thor

  • Published on 06/09/2025 at 15:00, 11 hours 55 minutes ago

    Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

  • Published on 06/09/2025 at 15:00, 11 hours 55 minutes ago

    NioCorp to Present at the New York 121 Investment Conference

View all ACCESSWIRE
EQS Group
  • Published on 06/09/2025 at 19:00, 7 hours 55 minutes ago

    PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 02 JUIN 2025 au 06 JUIN 2025

  • Published on 06/09/2025 at 18:18, 8 hours 37 minutes ago

    Funding Circle Holdings plc: POS-Transaction in Own Shares

  • Published on 06/09/2025 at 16:26, 10 hours 29 minutes ago

    Dalata Hotel Group PLC: HOL-Holding(s) in Company*

  • Published on 06/09/2025 at 15:25, 11 hours 30 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated

  • Published on 06/09/2025 at 15:24, 11 hours 30 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.

View all EQS
Les Echos
  • Published on 06/06/2025 at 18:08, 3 days 8 hours ago

    FSDV : point d’étape sur le projet de rapprochement entre FSDV et le Groupe BMG

  • Published on 06/06/2025 at 17:45, 3 days 9 hours ago

    Mai 2025

  • Published on 06/06/2025 at 17:45, 3 days 9 hours ago

    May 2025

  • Published on 06/06/2025 at 17:45, 3 days 9 hours ago

    Informations relatives au nombre total de droits de vote et d’actions 2025 05 31

  • Published on 06/06/2025 at 17:45, 3 days 9 hours ago

    Information concerning the total number of voting rights and shares 2025 05 31

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2025 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy